OPTUS Pharmaceutical KRX:131030KOSDAQ
옵투스제약 · Korean news coverage and regulatory filings, organized.
Articles, 24h0
Articles, 7 days5
DART filings, 7 days0
Articles tracked7since Sep 11
In Q2 2026, OPTUS Pharmaceutical reported revenue of ₩24.6bn, up 13.1% year on year, and operating profit of ₩2.3bn. OPTUS Pharmaceutical (옵투스제약) appeared in 5 Korean news articles and 0 DART filings over the past seven days. Coverage peaked on Oct 27 with 3 articles. The most common catalyst was clinical & approvals (3).
OPTUS Pharmaceutical quarterly results separate, KRW
| Quarter | Revenue | YoY | Operating profit | Net income |
|---|---|---|---|---|
| Q2 2026 | ₩24.6bn | +13.1% | ₩2.3bn margin 9.4% | ₩3.9bn |
| Q1 2026 | ₩23.2bn | +23.8% | ₩2.9bn margin 12.5% | ₩2.5bn |
| Q4 2025 derived | ₩22.6bn | -1.8% | ₩1.7bn margin 7.4% | ₩4.1bn |
| Q3 2025 | ₩24.1bn | +24.7% | ₩3.2bn margin 13.4% | ₩3.2bn |
| Q2 2025 | ₩21.8bn | +4.1% | ₩3.1bn margin 14.1% | ₩2.8bn |
| Q1 2025 | ₩18.7bn | +0.3% | ₩920m margin 4.9% | ₩1.2bn |
| Q4 2024 derived | ₩23.0bn | +15.6% | ₩3.0bn margin 13.2% | ₩4.0bn |
| Q3 2024 | ₩19.3bn | +5.5% | ₩1.3bn margin 6.6% | ₩1.5bn |
Key accounts from quarterly, half-year and annual reports filed on DART. Q4 is derived as full-year minus nine-month figures. Figures may differ from preliminary earnings releases. Margin is operating profit divided by revenue — see operating margin.
OPTUS Pharmaceutical top stories 2 weeks, by number of outlets
- 1
- 2
- 3
- 4
- 5
- 6
Latest OPTUS Pharmaceutical news Korean headlines
-
Major옵투스제약, 노안 치료제 ‘클로시’ 식약처 품목허가 신청
1 more on this story · 1 outlets
- 옵투스제약, 노안 치료제 'QLOSI' 국내 품목허가 신청메디파나뉴스 · Oct 27 17:53